Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.
Rapid Review
Commenced | Completed | Outcome |
15/11/2011 | 23/01/2012 | Full Pharmacoeconomic Evaluation Recommended |